Phase I/II Study of KP-100IT in Acute Spinal Cord Injury
Status:
Completed
Trial end date:
2018-07-31
Target enrollment:
Participant gender:
Summary
This study is randomized, double-blind, placebo-controlled Phase I/II study designed to
evaluate safety and efficacy of KP-100IT, code of Hepatocyte Growth Factor (HGF) formulation
for intrathecal injection, as a treatment for acute spinal cord injury. The study is
conducted at two clinical sites in Japan.